Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026
Post-COVID-19 onset of allergic conditions in a propensity-matched cohort of children and adults.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Clarion Jessica, Berill Zella, Susi Apryl, Mitre Edward, Schwartz David, Nylund Cade M
Аннотация
BACKGROUND: SARS-CoV-2 offers a new context to evaluate the relationship between viral infection and allergic disease. A biologically plausible mechanism exists for postinfectious type 2 helper T cell-skewed responses, among other forms of immune dysregulation; early studies suggest increases in asthma and other allergic or atopy-associated diagnoses after infection.
OBJECTIVE: To investigate whether COVID-19 infection predisposes individuals to developing allergic conditions.
METHODS: We conducted a 1:2 propensity-matched retrospective cohort study of individuals aged 1 to 64 years, evaluating the association between COVID-19 exposure and the development of incident allergic conditions (atopic dermatitis, asthma, food allergies, rhinoconjunctivitis, medication allergies, or urticaria) within a follow-up period of 18 months. We calculated hazard ratios for the incident outcomes of interest among the entire cohort, and in subanalyses of children and active-duty service members.
RESULTS: COVID-19 infection was associated with significantly increased hazard ratios for all six allergic conditions in the full cohort. Among the active-duty subset, asthma and rhinoconjunctivitis were significantly associated with infection. In children, all conditions except food allergy were significantly associated with infection. Higher sponsor rank, evaluated as a potential surrogate for socioeconomic status, showed a slight protective effect against the development of asthma.
CONCLUSION: This study adds to the growing body of evidence illustrating the risk of developing allergic conditions after COVID-19 infection in both children and adults. Our findings highlight the potential public health burden of these conditions, emphasize the importance of monitoring for allergic diseases after COVID-19 infection to enable prompt intervention, and suggest a mechanistic link between COVID-19 infection and type 2 inflammation.
OBJECTIVE: To investigate whether COVID-19 infection predisposes individuals to developing allergic conditions.
METHODS: We conducted a 1:2 propensity-matched retrospective cohort study of individuals aged 1 to 64 years, evaluating the association between COVID-19 exposure and the development of incident allergic conditions (atopic dermatitis, asthma, food allergies, rhinoconjunctivitis, medication allergies, or urticaria) within a follow-up period of 18 months. We calculated hazard ratios for the incident outcomes of interest among the entire cohort, and in subanalyses of children and active-duty service members.
RESULTS: COVID-19 infection was associated with significantly increased hazard ratios for all six allergic conditions in the full cohort. Among the active-duty subset, asthma and rhinoconjunctivitis were significantly associated with infection. In children, all conditions except food allergy were significantly associated with infection. Higher sponsor rank, evaluated as a potential surrogate for socioeconomic status, showed a slight protective effect against the development of asthma.
CONCLUSION: This study adds to the growing body of evidence illustrating the risk of developing allergic conditions after COVID-19 infection in both children and adults. Our findings highlight the potential public health burden of these conditions, emphasize the importance of monitoring for allergic diseases after COVID-19 infection to enable prompt intervention, and suggest a mechanistic link between COVID-19 infection and type 2 inflammation.